Blood Brain Barrier Differences in Patients with Brain Tumors Undergoing Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

54 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-09-20

Study Completion Date

2023-01-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This pilot research trial studies blood brain barrier differences in patients with brain tumors undergoing surgery. Studying samples of tissue and blood from patients with brain tumors in the laboratory may help doctors to understand how well drugs get into different parts of a brain tumor. This may help them to determine which types of drugs may be best for treating brain tumors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Detecting Abnormal Blood Clotting in Patients With Metastatic Cancer Undergoing Surgery

NCT00096590

Thromboembolism Unspecified Adult Solid Tumor, Protocol Specific

COMPLETED

Study of Tissue and Blood Samples From Patients With High-Grade Glioma

NCT01004887

Brain and Central Nervous System Tumors

COMPLETED

Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance

NCT00026663

Renal Cell Carcinoma Lung Carcinoma Cervical Carcinoma

COMPLETED

Study of Blood and Cheek Cell Samples From Patients With Glioma

NCT01009307

Brain and Central Nervous System Tumors

COMPLETED

Biomarker Analysis of Central Nervous System Tumors

NCT02692898

Central Nervous System Neoplasms Primary Brain Neoplasms Neoplasms, Brain +2 more

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVE:

I. To define the heterogeneity of blood brain barrier (BBB) permeability by assessing drug distribution in a population of patients with central nervous system (CNS) malignancy.

SECONDARY OBJECTIVE:

I. Establish correlation of BBB permeability with radiographic appearance for study patients.

CORRELATIVE RESEARCH OBJECTIVE:

I. To utilize tumor samples to investigate mechanisms for BBB heterogeneity.

OUTLINE:

As part of pre-operative standard of care, patients receive levetiracetam by injection and cefazolin by injection. Patients are also offered lorazepam in the pre-operative area. At the time of surgery, patients undergo approximately 2 tissue biopsies from 3-4 tumor locations. This tissue is removed as part of the planned surgery, but it is also tested for research purposes. During surgery, a blood sample is collected every 20-30 minutes beginning at the time of skin incision until all of the research tumor samples have been removed. A minimum of 3 blood samples are collected up to a maximum of 12.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Central Nervous System Neoplasm Localized Brain Neoplasm Metastatic Malignant Neoplasm in the Brain Recurrent Brain Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Observational (biospecimen collection)

As part of pre-operative standard of care, patients receive levetiracetam by injection and cefazolin by injection. Patients are also offered lorazepam in the pre-operative area. At the time of surgery, patients undergo approximately 2 tissue biopsies from 3-4 tumor locations. This tissue is removed as part of the planned surgery, but it is also tested for research purposes. During surgery, a blood sample is collected every 20-30 minutes beginning at the time of skin incision until all of the research tumor samples have been removed. A minimum of 3 blood samples are collected up to a maximum of 12.

Biospecimen Collection

Intervention Type PROCEDURE

Undergo collection of tissue and blood samples

Laboratory Biomarker Analysis

Intervention Type OTHER

Correlative studies

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biospecimen Collection

Undergo collection of tissue and blood samples

Intervention Type PROCEDURE

Laboratory Biomarker Analysis

Correlative studies

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Biological Sample Collection Biospecimen Collected Specimen Collection

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>= 18 years
* Clinical and radiographic evidence suggesting CNS malignancy
* Suspected newly diagnosed, local, or intracranial recurrence of primary brain tumor OR previously untreated or treated brain metastasis
* Willing to undergo a neurosurgical resection of CNS lesion at Mayo Clinic Rochester
* Able to have magnetic resonance imaging (MRI) imaging with gadolinium contrast (e.g. no cardiac pacemaker, defibrillator, renal failure)
* Females of childbearing potential must have a negative pregnancy test done =\< 14 days prior to registration
* Provide written informed consent
* Willing to provide tissue and blood samples for research purposes
* Patients having a study-specific surgical planning MRI only: Creatinine (estimated glomerular filtration rate \[eGFR\] \>= 30) (obtained =\< 30 days prior to registration)

Exclusion Criteria

* Vulnerable populations: pregnant women, prisoners, mentally handicapped
* Unable to undergo a biopsy of CNS lesion
* Documented drug allergy to cefazolin or levetiracetam, or other contraindication to use these drugs in the pre-operative setting (e.g., patient is already on another anti-seizure medication which precludes the clinical indication for pre-operative levetiracetam)
* Patients who are unable to swallow tablets if study drug is administered by mouth
* Patients who are at risk for impaired absorption of oral medication if study drug is administered by mouth; Note: This includes but not limited to, refractory vomiting, gastric resection/bypass, and duodenal/jejunal resection
* Pregnant or nursing women; Note: Pregnant women are excluded from this study because of the potential for teratogenic or abortifacient effects with chemotherapy; there is also a potential risk for adverse events (AEs) in nursing infants secondary to treatment of the mother with these drugs, so breastfeeding should be discontinued for the duration of the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No